Dyadic executed an OEM distribution agreement with IBT Bioservices to market recombinant DNase I and transferrin for research-use-only applications. Initial offerings include human and bovine transferrin alongside DNase I, leveraging IBT’s established sales channels to broaden product reach.

The partnership aligns with Dyadic’s strategy to shift from R&D-driven income to commercial product sales, generating recurring product-based revenue. It complements recent manufacturing expansions and enhances Dyadic’s ability to scale production and introduce additional cell culture–relevant proteins.

The agreement provides flexibility for future growth, including supply of market-ready products for distribution or licensing of production strains. This multi-channel approach supports long-term objectives to translate microbial platform capabilities into scalable revenue streams across life sciences and bioindustrial markets.